IP Library › Granted Patent US 12,648,907
Granted Patent B2
US 12,648,907 · App. 17/428,245 · Granted Jun 9, 2026

Membrane protein scaffolds for exosome engineering

Inventors: Kevin P. Dooley (Boston, MA); Douglas E. Williams (Boston, MA); James E. Thornton (Cambridge, MA)
Assignee: LONZA SALES AG
A61K9/127A61K35/15A61K35/28A61K47/62C07K14/70596A61K2035/124A61K38/00C07K2319/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,648,907
App. No.
17/428,245
Granted
Jun 9, 2026
Kind
B2
Abstract

The present disclosure relates to heterologous exosomal vesicle proteins (HEVPs), engineered exosomes comprising HEVPs, and methods of preparing and using these compositions, including therapeutic applications.

Claims (14)

1 . An extracellular vesicle (EV) comprising a heterologous CD13 protein, wherein the EV is produced from a producer cell which does not naturally express the CD13 protein, and wherein the EV further comprises a prostaglandin F2 receptor negative regulator (PTGFRN) protein.

2 . The EV of claim 1 , wherein the CD13 protein in the EV has a level of about 10 peptide spectral matches (PSMs) to about 1,000 PSMs, as measured using liquid chromatography with tandem mass spectrometry (LC-MS/MS).

3 . The EV of claim 1 , wherein the CD13 protein is a fusion protein.

4 . The EV of claim 3 , wherein the fusion protein comprises a functional moiety.

5 . The EV of claim 4 , wherein the functional moiety comprises an affinity tag, a therapeutic compound, a targeting moiety, or a combination thereof.

6 . The EV of claim 5 , wherein the therapeutic compound comprises a natural peptide, a recombinant peptide, a synthetic peptide, a nucleotide, an amino acid, a lipid, a carbohydrate, a small molecule drug, an antibody or a fragment thereof, an enzyme, a ligand, a receptor, or a combination thereof.

7 . The EV of claim 4 , wherein the fusion protein further comprises a linker.

8 . The EV of claim 7 , wherein the fusion protein is conjugated to the functional moiety by the linker.

9 . The EV of claim 7 , wherein the linker comprises a flexible linker, a rigid linker, a cleavable linker, or a combination thereof.

10 . The EV of claim 1 , wherein the producer cell comprises a human embryonic kidney (HEK) cell, or a Chinese hamster ovary (CHO) cell.

11 . The EV of claim 1 , wherein: (i) the producer cell is a non-human cell and the CD13 protein is a human CD13 protein; or (ii) the producer is a human cell and the CD13 protein is a non-human CD13 protein.

12 . The EV of claim 1 , wherein the CD13 protein comprises the amino acid sequence set forth in SEQ ID NO: 47.

13 . The EV of claim 1 , wherein the producer cell is a CHO cell.

14 . The EV of claim 1 , wherein the producer cell is a HEK cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2023
From: CODIAK BIOSCIENCES, INC.
To: LONZA SALES AG
Reel/Frame 064251/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2021
From: DOOLEY, KEVIN P.; WILLIAMS, DOUGLAS E.; THORNTON, JAMES E.
To: CODIAK BIOSCIENCES, INC.
Reel/Frame 057450/0502 →
Continuity (4)
Provisional Application 62851581 · May 22, 2019
Provisional Application 62801636 · Feb 5, 2019
Provisional Application 62801065 · Feb 4, 2019
Related Publication 20220249373A1 · Aug 11, 2022
References Cited (50)
US 10195290B1 · Dooley et al. · 2019 [cited by applicant]
US 10561740B2 · Dooley · 2020 [cited by examiner]
US 11679164B2 · Dooley · 2023 [cited by examiner]
US 12030924B2 · Lewis · 2024 [cited by examiner]
US 12257313B2 · Dooley · 2025 [cited by examiner]
US 12331100B2 · Lewis · 2025 [cited by examiner]
US 20100029585A1 · Howbert et al. · 2010 [cited by applicant]
US 20120219615A1 · Hershberg et al. · 2012 [cited by applicant]
US 20130202707A1 · Ali et al. · 2013 [cited by applicant]
US 20140356382A1 · Wood · 2014 [cited by examiner]
CA 3030342A1 · 2018 [cited by examiner]
WO WO2008115319A2 · 2008 [cited by applicant]
WO WO2009030996A1 · 2009 [cited by applicant]
WO WO2009088401A2 · 2009 [cited by applicant]
WO WO2011044246A1 · 2011 [cited by applicant]
WO 2015002956A1 · 2014 [cited by applicant]
WO WO2017203260A1 · 2017 [cited by applicant]
WO 2018011191A1 · 2018 [cited by applicant]
WO 2018015539A1 · 2018 [cited by applicant]
WO WO2018015535A1 · 2018 [cited by applicant]
WO WO2019040920A1 · 2019 [cited by applicant]
WO WO2019099942A1 · 2019 [cited by applicant]
WO WO2020163370A1 · 2020 [cited by applicant]
Doron, “Bacterial Infections: Overview,” International encyclopedia of Public health, 2008:273-282 (Year: 2008). [cited by examiner]
National Institute of Cancer—understanding and related topics, accessed Aug. 21, 2014 at URL: cancer.gov/cancertopics/understandingcancer, 63 pages (Year: 2014). [cited by examiner]
Viruses overview, Merck Manual, accessed Feb. 19, 2019 at URL merckmanuals.com/professional/infectious-diseases/viruses/overview-of-viruses, 6 pages (Year: 2019). [cited by examiner]
Margolis, “Diagnosis of Huntington disease,” Clin. Chem. 49:1726-32 (2003) (Year: 2003). [cited by examiner]
Alzheimer's disease, Merck Manual, accessed Nov. 2, 2023 at URL merckmanuals.com/professional/neurologic-disorders/delirium-and-dementia/alzheimer-disease, pp. 1-9 (Year: 2023). [cited by examiner]
Metabolic disease, Encyclopedia Britannica, accessed Feb. 12, 2020 at URL: britannica.com/science/metabolic-disease; pp. 1-17 (2019 ) (Year: 2019). [cited by examiner]
Rountree et al., “Exosome Targeting of Tumor Antigens Expressed by Cancer Vaccines Can Improve Antigen Immunogenicity and Therapeutic Efficacy,” Can Res 15:5235-5244 (2011) (Year: 2011). [cited by examiner]
Drumm et al, Genetic Variation and Clinical Heterogeneity in Cystic Fibrosis, Annu. Rev. Pathol. Mech. Dis., 2012, 7, pp. 267-282 (Year: 2012). [cited by examiner]
Yampolsky et al, The Exchangeability of Amino Acids in Proteins, Genetics, 2005, 170, pp. 1459-1472. (Year: 2005). [cited by examiner]
Banaszynski, L.A., et al., “Characterization of the FKBP.rapamycin.FRB Ternary Complex,” Journal of the American Chemical Society 127(13):4715-4721, American Chemical Society, United States (Apr. 2005). [cited by applicant]
Chen, X., et al., “Fusion Protein Linkers: Property, Design and Functionality,” Advanced Drug Delivery Reviews 65(10):1357-1369, Elsevier Science Publishers, B.V., Netherlands (Oct. 2013). [cited by applicant]
Corpet, F., “Multiple Sequence Alignment With Hierarchical Clustering,” Nucleic Acids Research 16(22):10881-10890, Oxford University Press, England (Nov. 1988). [cited by applicant]
Dobeli, H., et al., “Role of the Carboxy-terminal Sequence on the Biological Activity of Human Interferon (IFN-y),” Journal of Biotechnology 7:199-216, Elsevier, Netherlands (Mar. 1988). [cited by applicant]
Frank, A.M., “A Ranking-based Scoring Function for Peptide-spectrum Matches,” Journal of Proteome Research 8(5):2241-2252, American Chemical Society, United States (May 2009). [cited by applicant]
Gayle, R.B., III., et al., “Identification of Regions in Interleukin-1 Alpha Important for Activity,” The Journal of Biological Chemistry 268(29):22105-22111, Elsevier Inc. on behalf of American Society for Biochemistry… [cited by applicant]
Gupta, S.C., et al., “Inhibiting NF-κB Activation by Small Molecules as a Therapeutic Strategy,” Biochimica Et Biophysica Acta 1799(10-12):775-787, Elsevier Pub. Co., Netherlands (Oct.-Dec. 2010). [cited by applicant]
Higgins, D.G. and Sharp, P.M., “Clustal: A Package for Performing Multiple Sequence Alignment on a Microcomputer,” Gene 73(1):237-244, Elsevier/North-Holland, Netherlands (Dec. 1988). [cited by applicant]
Higgins, D.G. and Sharp, P.M., “Fast and Sensitive Multiple Sequence Alignments on a Microcomputer,” Computer Applications in the Biosciences 5(2):151-153, Oxford University Press, England (Apr. 1989). [cited by applicant]
Huang, X., et al., “Parallelization of a Local Similarity Algorithm,” Computer Applications in the Biosciences 8(2):155-165, Oxford University Press, England (Apr. 1992). [cited by applicant]
International Search Report and Written Opinion mailed May 8, 2020 in International Application No. PCT/US2020/016629, EPO, Netherlands, 10 pages. [cited by applicant]
Kuypers, F.A., et al., “Survival of Rabbit and Horse Erythrocytes in Vivo after Changing the Fatty Acyl Composition of their Phosphatidylcholine,” Biochimica et Biophysica Acta 819(2):170-178, Elsevier Pub. Co., Netherl… [cited by applicant]
Mei, B., et al., “Rational Design of a Fully active, Long-acting PEGylated Factor VIII for Hemophilia A Treatment,” Blood 116(2):270-279, The American Society of Hematology, United States (Jul. 2010). [cited by applicant]
Needleman, S.B. and Wunsch, C.D., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” Journal of Molecular Biology 48(3):443-453, Academic Press, United Kingdom (Mar.… [cited by applicant]
Pearson, W.R., “Using the FASTA Program to Search Protein and DNA Sequence Databases,” Methods in Molecular Biology 24:307-331, Humana Press, United States (Feb. 1994). [cited by applicant]
Pitt, J.M., et al., “Dendritic Cell-Derived Exosomes for Cancer Therapy,” The Journal of Clinical Investigation 126(4):1224-1232, American Society for Clinical Investigation, United States (Apr. 2016). [cited by applicant]
Ron, D., et al., “Expression of Biologically Active Recombinant Keratinocyte Growth Factor. Structure/Function Analysis of Amino-terminal Truncation Mutants,” The Journal of Biological Chemistry 268(4):2984-2988, Elsevi… [cited by applicant]
Smith, T.F. and Waterman, M.S., “Comparison of Biosequences,” Advances in Applied Mathematics 2(4):482-489, Academic Press, Inc., United States (Dec. 1981). [cited by applicant]